BLANK, Michael et al.
 Hypericin targets multiple signaling mediators in cancer cells generating unique, diverse anti-tumoral, anti-metastatic, and anti-angiogenic activities with evidence for clinical applicability.
<strong>Medical Research Archives</strong>, [S.l.], v. 5, n. 3, mar. 2017.
ISSN 2375-1924.
Available at: &lt;<a href="https://esmed.org/MRA/mra/article/view/881" target="_new">https://esmed.org/MRA/mra/article/view/881</a>&gt;. Date accessed: 18 nov. 2024.